Recently, Shenzhen Shuangka Kangsui Biomedical Co., Ltd., a company under the Deep Harbour Cell Valley , announced the completion of a seed funding round of nearly 10 million yuan. This round of financing will primarily be used to advance the research and development, process scale-up, and preclinical studies of an innovative cell therapy product targeting acute myeloid leukemia (AML) based on the CD146 target, laying a solid foundation for subsequent clinical translation.

Shenzhen Shuangka Kangsui Biomedical Co., Ltd. was jointly established by Deep Harbour Cell Valley Healthcare and Technology Co.Ltd, Zhongyuan Nanoenzyme Laboratory (Zhengzhou) Co., Ltd., and Beijing Yishi Biotechnology Co., Ltd. Located in the Qianhai Free Trade Zone of Shenzhen, it represents a significant strategic deployment by Deep Harbour Cell Valley in the high-barrier segment of hematologic oncology.

The core technology of the company originates from the systematic research achievements of over two decades by the team led by Academician Yan Xiyun of the Chinese Academy of Sciences on the CD146 molecule. The team led by Academician Yan Xiwu was the first globally to systematically elucidate the critical regulatory role of CD146 within the tumor immune microenvironment and the 'tumor niche.' This breakthrough offers a completely novel therapeutic strategy to address long-standing clinical challenges in Acute Myeloid Leukemia (AML), including the lack of ideal targets, high relapse rates, and strong drug resistance.

Based on this foundation, Shenzhen Shuangka Kangsui focuses on the innovative strategy of "Niche-Targeting." Centering on targets such as CD146 in combination with CLL1, the company has systematically established a pipeline of cell therapy products, including CAR-T and CAR-NK. This approach aims to achieve the "dual elimination" of both tumor cells and the stromal cells within the microenvironment that support their survival. To reduce relapse risk at the mechanistic level and develop a specialized AML cell therapy regimen with potential international competitiveness.

As an important supporter for the industrialization and clinical translation of the project, Deep Harbour Cell Valley will rely on its accumulated capabilities in the industrial production of GMP-grade viral vectors, cell drug process development systems, and clinical translation experience in the field of cell and gene therapy. It will be fully responsible for drug design, CMC development, non-clinical research, and the advancement of clinical studies, so as to accelerate the translation of scientific research achievements into standardized clinical applications.

Dr. Zhu Wenxiang , a relevant person in charge of Shenzhen Shuangka Kangsui Biomedical Co., Ltd., stated:“The completion of this seed round financing marks that CD146-targeted cell therapy has moved from long-term basic research to a new stage of systematic industrial transformation.In the future, the company will continue to collaborate with the academician team and top clinical hematology centers to steadily advance IIT and subsequent registered clinical studies, striving to provide truly breakthrough treatment options for AML patients.”

Against the backdrop of a continuously improving policy environment for the cell and gene therapy industry in China and the ongoing development of the Shenzhen‑Hong Kong collaborative innovation system, the recent financing and project advancement of Shenzhen Shuangka Kangsui Biomedical  are regarded as another important achievement of the integrated platform model of "Original Innovation + Engineering Capability + Clinical Translation" at Deep Harbour Cell Valley.

Key members of the project team. The two in the middle are Academician Yan Xiyun and Professor Shi Yuanyuan.

Zhongyuan Nanozyme Laboratory (Zhengzhou) Co., Ltd. is a sci-tech achievement industrialization and operation entity wholly owned by Zhongyuan Nanozyme Laboratory (a Henan Provincial Laboratory and public institution). Established in October 2023, the laboratory is headed by Academician Yan Xiyun of the Chinese Academy of Sciences.

Led by the Henan Academy of Medical Sciences, Zhengzhou University and Henan University, the laboratory integrates scientific and technological resources from universities and research institutes including Henan Agricultural University and the First Affiliated Hospital of Zhengzhou University. Following the principle of “complementary strengths”, Zhongyuan Nanozyme Laboratory will industrially produce nitrogen-fixing nanozymes via a globally unique core technological route.It aims to build a world-leading platform for basic theoretical research on nanozymes, a common technology R&D platform, and a sci-tech enterprise incubation platform, forge an international first-class innovation highland for nanozymes, and develop a world-renowned industrialization service base for R&D and application of biotechnology. It will open up a new path for the high-quality development of the biomedicine industry. In the future, it will also incubate a number of high-tech enterprises related to nanozymes, striving to promote nanozyme technology to benefit the people.